New KPIs May Cut Post-Endoscopy GI Cancer Risk
A consensus on major and minor key performance indicators (KPIs) was established to improve the quality of upper gastrointestinal (GI) endoscopy and reduce post-endoscopy upper GI cancer. The adoption of the proposed recommendations could minimise the threefold variation in post-endoscopy cancer rates among providers in England.
METHODOLOGY:
Researchers identified potential KPIs from the systematic review (up to December 2021), National Cancer Registry and Hospital Episode Statistics Database Analysis, and National Endoscopy Database Analysis.
The cancer registry analysis included the data of 98,801 patients diagnosed with upper GI cancer within 3 years of a cancer-negative endoscopy in England between 2009 and 2018.
Researchers used the modified nominal group technique through two online workshops moderated by James Lind Alliance facilitators. Overall, this study included 14 clinicians, three nurse endoscopists, two upper GI cancer nurse specialists, 14 patients and their relatives and representatives, and four observers.
KPIs were categorised as endoscopy provider or endoscopist/procedure related.
The ranking of KPIs was based on their relative importance in reducing post-endoscopy upper GI cancer, where the top 10 with lower scores were designated as major indicators and the remaining ones minor.
TAKEAWAY:
Four major provider-related KPIs were identified, of which the monitoring of post-endoscopy upper GI cancer rates with minimum standards of 7% or less and maintaining less intense endoscopy lists with less than 10 points per list were ranked the highest.
A total of six major endoscopist-related KPIs were specified, of which adequate examination time of at least 7 minutes and dedicated training in the recognition of early upper GI neoplasia were ranked the highest.
Five KPIs were ranked as minor, which included the detection rate for premalignant conditions, use of image enhancement techniques, photo documentation of anatomical sites for minimum standards of more than 90% of diagnostic upper GI endoscopies, neoplasia detection rate, and use of artificial intelligence.
IN PRACTICE:
"This consensus provides a list of major and minor KPIs to improve the quality of endoscopy and reduce PEUGIC [post-endoscopy upper GI cancer]," the authors wrote, suggesting that, "this framework will enable endoscopy providers to monitor their performance and ensure the provision of a high-quality UGI endoscopy service for their patients."
SOURCE:
This study was led by Umair Kamran, Sandwell and West Birmingham NHS Trust, Birmingham, England. It was published online on July 24, 2025, in United European Gastroenterology Journal.
LIMITATIONS:
Most of the evidence examined was graded as low-to-moderate quality due to the lack of well-designed trials. The applicability of the recommendations may be limited outside the UK because the consensus included only UK participants. Additional limitations included insufficient evidence to suggest minimum standards for some measures and bias in consensus statements due to weak evidence.
DISCLOSURES:
This study received funding from the National Institute for Health and Care Research under its Research for Patient Benefit Programme. The authors declared having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker. Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at and follow us on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investors and MediaNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
A cancer diagnosis can cause out-of-pocket costs to surge, study finds
A cancer diagnosis increases privately insured patients' monthly out-of-pocket costs, which also rise as the disease progresses, new research shows. Out-of-pocket costs jumped by $592.53 per month for the six months after a diagnosis, according to a recent report published in JAMA Open Network. The study underscores the financial toll a cancer diagnosis can take on individuals, even for those who are insured but don't yet qualify for Medicare. While cancer tends to strike later in life, when most patients in treatment are receiving Medicare benefits, a cancer diagnosis can pose an undue financial burden on younger people with private insurance, the report found. Those out-of-pocket costs highlight the need for policy reform, the report said. The research "underscores the need for policies such as paid sick leave that address both insurance continuity and financial assistance, especially for patients with more advanced cancer," the report states. Out-of-pocket costs increased based on a patient's cancer progression, the analysis found. Patients with stage 0 cancer saw their costs rise by $462 per month compared to non-cancer patients, while stage 4 cancer cost people with private insurance an additional $719.97 per month in out of pocket costs. Costs rise as the disease progresses because patients typically require more treatment during cancer's later stages, leading to greater medical expenditures. "This result seems straightforward; later-stage disease is associated with more intensive workup and treatment that can drive higher medical expenditures," the report states. Researchers analyzed medical claims records from the Surveillance, Epidemiology, and End Results (SEER) cancer registry to compare the out-of-pocket costs of privately insured individuals under the age of 65 who were diagnosed with breast, colorectal, and lung cancer, to those without cancer. New research from the American Cancer Society shows that as more people aged 45-49 undergo screening for colon cancer, more early stage diagnoses are being made. DOGE savings are a fraction of what the department claims, CBS News analysis finds Details on House subpoenas for Clintons and others over Epstein files Trump doubles down on decision to fire labor statistics chief Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
RSV symptoms as 'serious virus' coming to UK after Australia surge
NHS experts have urged people who are eligible for a vaccine against respiratory syncytial virus (RSV) to take it up after cases surged in Australia. Australia saw a record number of RSV cases last year, and NHS officials have suggested that the Australian winter often provides a good indication of how viruses will spread in England. Since the start of 2025, the virus has been progressively spreading, with nearly half of reported cases occurring in children under five years old. Kate Brintworth, chief midwifery officer for NHS England, said: "Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating." READ MORE: Walker spots giant 'alien' jellyfish washed up on beach READ MORE: Warning over serious virus affecting newborns after surge in cases Dr Andy Whittamore, GP and clinical lead at Asthma + Lung UK, who has pointed out the key symptoms to watch out for and shared some strategies to help protect yourself and your family. What is RSV? He said: "Respiratory syncytial virus is a virus that causes symptoms very similar to the common cold, most of us get it at some point and don't even know that we've had it." According to Asthma + Lung UK, up to 9 in 10 children will contract RSV before they turn two years old and around 175,000 people over the age of 65 visit their GP about RSV each year. How does it spread? Dr Whittamore said: "Like most respiratory viruses, RSV spreads by people coughing and sneezing droplets from their own respiratory tract and it is spread to other people that way, It is often spread and caught in the air, by contact or if it ends up on surfaces." While RSV can circulate all year round, it typically peaks during the colder months. He said: "We see a major peak in cases in the NHS between October and February, particularly in December/January time." What are the most common symptoms? "As a GP, I see a lot of people with respiratory viruses and you can't really tell whether it's flu, Covid, RSV or the common cold," Dr Whittamore says. "Common symptoms are a runny nose, blocked nose, sneezing, coughing, feeling tired etc. People might also have a fever with it and if it's affecting their respiratory system itself, they might experience breathless or wheezing as well." A high temperature is also another key sign to look out for, according to the NHS website. Dr Whittamore said: "For most people, these symptoms tend to last no more than a week to 10 days." Can it lead to any serious complications? RSV can lead to some serious complications such as pneumonia or bronchiolitis for high-risk groups such as babies, young children and older people. Dr Whittamore said: "What we see with RSV, especially in younger children under the age of two, is that it can cause bronchiolitis, which causes quite dramatic breathing effects which can quite often put people in hospital. "We are also seeing that RSV is having a big impact on people over 75. We know that in that age group, the virus is more likely to cause them problems with their breathing and could go on and cause pneumonia and is likely to increase their chances of going to hospital." The NHS website also states that individuals with weakened immune systems, or long-term lung or heart conditions, and those who smoke tobacco are also at risk. A more serious infection (such as pneumonia or bronchiolitis) may cause a cough that gets worse, shortness of breath, noisy breathing (wheezing), faster breathing or long gaps between breaths, difficulty feeding in babies or loss of appetite, and confusion in older adults, according to the NHS website. How is it treated? RSV often improves on its own in one or two weeks, so you can usually manage it at home. Dr Whittamore said: "One important thing to do is to keep well hydrated, people with RSV should be pushing their fluids, resting more, taking paracetamol and can usually monitor themselves. However, if you are worried about yourself or your child, then seek advice from your GP or call 111." Can it be prevented? There are some measures you can take to reduce your chances of contracting RSV or spreading it to anyone else. Dr Whittamore said: "Make sure that when you are blowing your nose or sneezing that you use a tissue and throw it away, also, remember to wash your hands and clean surfaces regularly." The GP emphasises that the most crucial way to prevent people from falling ill with RSV is to ensure you receive the RSV vaccination if you are eligible for it. The RSV jab is recommended if you're expecting (from 28 weeks of pregnancy) – to help safeguard your baby for the first few months after they're born – or if you're aged between 75 and 79. Fresh research from the UK Health Security Agency (UKHSA) has revealed the RSV vaccine is around 82% effective in preventing older people being hospitalised with an RSV infection. "Most GP practices are contacting people and inviting them in, but if somebody thinks they're eligible and haven't been contacted they should contact their GP surgery and see if they can get it booked in," recommends Dr Whittamore.
